• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.79 -0.20 (-0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating ↗
July 04, 2026
Via Chartmill
News headline image
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore
June 29, 2026
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off
June 26, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
June 24, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
June 11, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals ↗
June 10, 2026
Via Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth ↗
May 19, 2026
Via Chartmill
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance ↗
May 04, 2026
Via Chartmill
Topics Earnings
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
May 30, 2026
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today
May 21, 2026
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company announced positive resu... 
Via StockStory
News headline image
1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky
May 21, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down
May 14, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas... 
Via StockStory
Topics Credit Cards
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock ↗
April 17, 2026
Via Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
March 16, 2026
Via Chartmill
News headline image
BioMarin Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
May 11, 2026
BioMarin’s first quarter saw revenue growth driven by continued demand for its enzyme therapies and Voxzogo, but the company missed Wall Street’s revenue and... 
Via StockStory
Topics Earnings
News headline image
BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook
May 05, 2026
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.8% year on year to $766.2 millio... 
Via StockStory
News headline image
BioMarin (BMRN) Q1 2026 Earnings Transcript ↗
May 04, 2026
BioMarin (BMRN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates
May 04, 2026
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.8% year on year to $766.2 millio... 
Via StockStory
News headline image
BioMarin (BMRN) Q4 2025 Earnings Transcript ↗
May 04, 2026
BioMarin (BMRN) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect
May 02, 2026
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Monday afternoon. Here’s what to look for. BioMarin Pharmaceutical beat ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
April 13, 2026
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
Via MarketMinute
Topics Economy
News headline image
2 Profitable Stocks with Promising Prospects and 1 Facing Challenges
April 08, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
April 02, 2026
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Government Stocks World Trade
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky
March 26, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
March 20, 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
March 20, 2026
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
Via The Motley Fool
News headline image
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks
March 19, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD... 
Via StockStory
Topics Artificial Intelligence
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
March 16, 2026
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology. 
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
March 16, 2026
This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap